Teri Loxam Sells 6,250 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) Director Teri Loxam sold 6,250 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the transaction, the director now directly owns 7,175 shares of the company's stock, valued at $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Vaxcyte Trading Down 2.9 %

Shares of Vaxcyte stock traded down $2.53 during trading on Friday, hitting $85.30. 1,612,117 shares of the stock were exchanged, compared to its average volume of 1,259,638. The company has a fifty day moving average price of $88.51 and a 200-day moving average price of $93.49. The stock has a market capitalization of $10.63 billion, a price-to-earnings ratio of -18.54 and a beta of 0.98. Vaxcyte, Inc. has a 1-year low of $58.10 and a 1-year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period in the prior year, the business posted ($0.91) earnings per share. Equities research analysts forecast that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Vaxcyte

Several hedge funds have recently added to or reduced their stakes in PCVX. Janus Henderson Group PLC raised its position in shares of Vaxcyte by 23.1% in the third quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company's stock valued at $1,247,954,000 after purchasing an additional 2,052,989 shares during the period. RA Capital Management L.P. grew its stake in Vaxcyte by 5.9% in the 3rd quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company's stock valued at $992,914,000 after buying an additional 485,436 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Vaxcyte by 47.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company's stock valued at $148,075,000 after buying an additional 419,600 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Vaxcyte in the 3rd quarter valued at about $41,114,000. Finally, Maverick Capital Ltd. lifted its position in Vaxcyte by 93.7% during the second quarter. Maverick Capital Ltd. now owns 687,908 shares of the company's stock worth $51,944,000 after acquiring an additional 332,777 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Analyst Ratings Changes

Several research analysts recently commented on PCVX shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Needham & Company LLC restated a "buy" rating and issued a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, The Goldman Sachs Group assumed coverage on Vaxcyte in a research report on Friday, December 20th. They issued a "buy" rating and a $135.00 target price on the stock. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $145.71.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.